Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-908 in Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT06074107Phase 2Completed
- Sponsor
- BeBetter Med
- Start
- Jun 2020
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
A Phase 2 trial of ifupinostat in diffuse large B-cell lymphoma, sponsored by BeBetter Med. Started Jun 2020; status: completed.
02
Drugs
ifupinostat
03
Conditions
diffuse large B-cell lymphoma
Beyond the preview
Go deeper on NCT06074107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06074107.